Theratechnologies Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer [Yahoo! Finance]
Theratechnologies Inc. - Common Shares (THTX)
Company Research
Source: Yahoo! Finance
First patient out of six already enrolled and treated with initial dose of 2.50 mg/kg/dose MONTREAL, March 21, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced moving to the next dose level in Part 3 of its Phase 1 clinical trial of sudocetaxel zendusortide in patients with advanced ovarian cancer. The study's Medical Review Committee (MRC) has deemed the dose level in the first cohort of patients safe and has approved initiation of the next cohort with an increased dose, in accordance with the updated dose optimization protocol. Study centers are now actively recruiting patients for the second cohort, with one patient already enrolled and treated with the higher dose. “We are encouraged by the safety and tolerability of the sudocetaxel zendusortide regimen in the first cohort of six patients in Part
Show less
Read more
Impact Snapshot
Event Time:
THTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
THTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
THTX alerts
High impacting Theratechnologies Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
THTX
News
- Theratechnologies (THTX) Upgraded to Buy: What Does It Mean for the Stock? [Yahoo! Finance]Yahoo! Finance
- Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders [Yahoo! Finance]Yahoo! Finance
- Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders [Financial Post (Toronto, Ontario, Canada)]Financial Post
- Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of ShareholdersGlobeNewswire
- Theratechnologies to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference [Financial Post (Toronto, Ontario, Canada)]Financial Post
THTX
Sec Filings
- 4/15/24 - Form 6-K
- 4/10/24 - Form 6-K
- 4/10/24 - Form 6-K
- THTX's page on the SEC website